Towards selectivity in cancer chemotherapy: a biochemical overview.
D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism; D010984:Platinum / Q000627:therapeutic use; D014176:Protein Biosynthesis; D014158:Transcription, Genetic; D014226:Triazenes / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use
D058892:Adenosine Deaminase Inhibitors; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D009363:Neoplasm Proteins; D014226:Triazenes; D014227:Triazines; D010984:Platinum; D008727:Methotrexate